Eli Lilly and Co
We’re starting a new position in one of the Big 3 global medical imaging and diagnostics companies
This company operates in an $84 billion total addressable market that the company sees growing to around $100 billion by 2024. Source
Read More
Oppenheimer says investors are missing opportunities in three biotech areas and the related stocks
As biopharma investors follow the latest buzz around advancements in clinical research, they may be under-appreciating opportunities in neurology, psychiatry and genetic medicine, according to a report from Oppenheimer. Specifically, analyst Jay Olson called out companies such as Biogen , Karuna Therapeutics and Crispr Therapeutics , among others. “Our analysis shows Genetic Medicine and Metabolic […]
Read More
Alzheimer’s treatment Leqembi could cost Medicare up to $5 billion per year, study estimates
The Alzheimer’s drug LEQEMBI is seen in this undated handout image obtained by Reuters on January 20, 2023. Eisai | Reuters The new Alzheimer’s antibody treatment Leqembi could cost Medicare up to $5 billion per year, according to research published in a leading medical journal this week. Medicare would spend about $2 billion per year […]
Read More
Eli Lilly CEO vows not to raise insulin prices again, while Novo Nordisk and Sanofi hedge
Eli Lilly CEO Dave Ricks on Wednesday promised not to raise prices on the company’s existing insulin products again — the only executive to do so before a Senate Health Committee hearing on making the life-saving diabetes drug more affordable. Sen. Bernie Sanders, the committee’s chair, asked Ricks and the CEOs of Novo Nordisk and […]
Read More
FDA commissioner praises Eli Lilly Alzheimer’s treatment results
FDA Commissioner Dr. Robert Califf speaks at an event celebrating hearing aids being available over the counter at a Walgreens in Washington, D.C., Oct. 19, 2022. Nathan Posner | Anadolu Agency | Getty Images Food and Drug Commissioner Dr. Robert Califf praised results Eli Lilly announced Wednesday that a clinical trial showed its Alzheimer’s treatment […]
Read More
Stocks making the biggest moves midday: CVS Health, Eli Lilly, Clorox, Yum and more
In this article SBUX GNRC LLY YUM PACW AMD Follow your favorite stocksCREATE FREE ACCOUNT A CVS pharmacy stands in a Brooklyn neighborhood on February 08, 2023 in New York City. Spencer Platt | Getty Images Check out the companies making the biggest moves midday: CVS Health — Shares fell about 3% after the company […]
Read More
Shares producing the biggest moves premarket: Starbucks, AMD, Pearson, PacWest & extra
In this short article GNRC CCOI PACW Follow your most loved stocksGenerate No cost ACCOUNT basic watch of a Starbucks retail outlet on September 15, 2022 in Plainview, New York Bruce Bennett | Getty Visuals Information | Getty Illustrations or photos Verify out the businesses making headlines in premarket trading. Eli Lilly — The pharmaceutical […]
Read More
Eli Lilly Alzheimer’s treatment donanemab slowed ailment progression in clinical trial
An Eli Lilly and Organization pharmaceutical production plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. Mike Segar | Reuters The Alzheimer’s treatment method donanemab, which is manufactured by Eli Lilly, appreciably slowed development of the brain-robbing disease, according to scientific demo info introduced Wednesday by the firm. Individuals who […]
Read More
Alzheimer’s patients may wait years to get treated with new drugs, putting them at risk of more severe disease
Juanmonino | E+ | Getty Images Seniors with early Alzheimer’s disease will face major hurdles to get treated even if promising new drugs roll out more broadly in the coming years, putting them at risk of developing more severe disease as they wait months or perhaps years for a diagnosis. The U.S. health-care system is […]
Read More